Abstract
The immunosuppressive action of hyperbaric oxygen (HBOX) has been proved by experimental studies in allergic encephalomyelitis [1] and other pathologies. Since 1970, clinical studies, most of them uncontrolled and nonblind, have been set up to evaluate the possible efficacy of HBOX in patients with multiple sclerosis (MS). The results have been controversial: some trials reported a positive action of HBOX [2] while others have not shown any clinical improvement [3].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
